Mesoblast Ltd (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Ltd (ASX: MSB)
Latest News
Share Market News
Why the Polynovo share price is now up 24x in 5 years
Share Fallers
Why Mesoblast, NAB, Nearmap, & Santos shares crashed lower today
Share Fallers
Why the Mesoblast share price crashed 10% lower today
Share Market News
Mesoblast shares halted as it asks investors to tip in another $75 million
Share Market News
Paradigm reports "ground-breaking" osteoarthritis discovery: Is it the real deal?
Share Market News
Is Paradigm Biopharmaceuticals the share market's next huge winner?
Share Gainers
Why Blackmores, Class, Mesoblast, & St Barbara shares raced higher today
Share Gainers
Why Mesoblast, New Hope, Pilbara Minerals, & Syrah shares charged higher today
Share Market News
Paradigm share price tanks despite positive clinical trial update
Share Market News
Why the Mesoblast share price is going nuts today
Share Gainers
Why iSignthis, Leigh Creek, Mesoblast, & Santos shares charged higher
Share Gainers
Mesoblast share price rockets 17% higher on Grünenthal partnership news
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Mesoblast Ltd
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
MSB Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
13 May 2024 | $1.05 | $-0.02 | -1.88% | 6,155,505 | $1.08 | $1.08 | $1.02 |
10 May 2024 | $1.07 | $-0.03 | -2.75% | 7,517,387 | $1.10 | $1.13 | $1.05 |
09 May 2024 | $1.09 | $-0.04 | -3.54% | 9,616,881 | $1.12 | $1.14 | $1.09 |
08 May 2024 | $1.13 | $-0.05 | -4.26% | 10,699,296 | $1.18 | $1.19 | $1.12 |
07 May 2024 | $1.18 | $0.02 | 1.73% | 14,047,015 | $1.20 | $1.21 | $1.17 |
06 May 2024 | $1.16 | $0.07 | 6.45% | 17,944,902 | $1.12 | $1.20 | $1.11 |
03 May 2024 | $1.09 | $0.01 | 0.93% | 10,528,006 | $1.11 | $1.12 | $1.08 |
02 May 2024 | $1.07 | $-0.03 | -2.73% | 29,220,535 | $1.11 | $1.21 | $1.05 |
01 May 2024 | $1.10 | $0.11 | 11.11% | 22,061,544 | $0.97 | $1.11 | $0.96 |
30 Apr 2024 | $0.99 | $-0.10 | -9.22% | 25,912,213 | $1.12 | $1.12 | $0.98 |
29 Apr 2024 | $1.09 | $0.16 | 17.20% | 27,375,536 | $0.95 | $1.09 | $0.94 |
26 Apr 2024 | $0.93 | $0.02 | 2.19% | 8,522,887 | $0.93 | $0.95 | $0.89 |
24 Apr 2024 | $0.92 | $0.02 | 2.22% | 7,616,298 | $0.92 | $0.94 | $0.89 |
23 Apr 2024 | $0.90 | $0.11 | 13.84% | 12,954,191 | $0.83 | $0.91 | $0.83 |
22 Apr 2024 | $0.80 | $0.03 | 3.92% | 4,496,481 | $0.79 | $0.81 | $0.78 |
19 Apr 2024 | $0.77 | $-0.01 | -1.29% | 6,472,845 | $0.77 | $0.80 | $0.76 |
18 Apr 2024 | $0.78 | $0.03 | 4.00% | 7,394,392 | $0.76 | $0.80 | $0.76 |
17 Apr 2024 | $0.75 | $-0.02 | -2.60% | 8,171,310 | $0.77 | $0.77 | $0.71 |
16 Apr 2024 | $0.77 | $-0.06 | -7.23% | 12,247,960 | $0.80 | $0.81 | $0.75 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
08 May 2024 | Eric Rose | Buy | 19,734 | $151,207 |
On-market trade. US$
|
30 Apr 2024 | Eric Rose | Buy | 21,428 | $142,318 |
On-market trade. US$ ADS
|
12 Apr 2024 | Jane Bell | Buy | 233,918 | $199,999 |
On-market trade.
|
10 Jan 2024 | William (Bill) Burns | Issued | 409,651 | $116,750 |
Issue of options.
|
10 Jan 2024 | Jane Bell | Issued | 326,729 | $93,117 |
Issue of options.
|
10 Jan 2024 | Joseph Swedish | Issued | 827,077 | $235,716 |
Issue of options.
|
10 Jan 2024 | Eric Rose | Issued | 1,960,765 | $558,818 |
Issue of options.
|
10 Jan 2024 | Silviu Itescu | Issued | 3,693,070 | $1,052,524 |
Issue of options.
|
10 Jan 2024 | Philip Facchina | Issued | 290,432 | $82,773 |
Issue of options.
|
29 Dec 2023 | Joseph Swedish | Buy | 850 | $917 |
On-market trade. US$
|
28 Dec 2023 | Jane Bell | Issued | 61,905 | $18,571 |
Rights issue.
|
28 Dec 2023 | Joseph Swedish | Buy | 91,035 | $99,082 |
On-market trade. US$
|
28 Dec 2023 | William (Bill) Burns | Issued | 21,250 | $6,375 |
Rights issue.
|
28 Dec 2023 | Philip Krause | Buy | 37,500 | $41,536 |
On-market trade. US$
|
21 Dec 2023 | Philip Facchina | Sell | 30,000 | $32,395 |
On-market trade. US$, As per announcement on 28-12-2023
|
12 Dec 2023 | Silviu Itescu | Issued | 10,000,000 | $3,000,000 |
Rights issue.
|
07 Jul 2023 | Silviu Itescu | Issued | 2,325,000 | $2,627,250 |
Issue of options.
|
07 Jul 2023 | Eric Rose | Issued | 2,150,000 | $2,429,500 |
Issue of options.
|
05 Jun 2023 | Philip Krause | Buy | 20,000 | $74,100 |
On-market trade. US$, 100,000 ordinary shares held in the form of 20,000 ADSs
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Professor Silviu Itescu | Chief Executive OfficerExecutive Director | Jun 2004 |
Dr. Itescu has served on the Board of Directors since the Company's founding. Dr Itescu established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican's Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy.
|
Dr Eric A Rose | Non-Executive Director | Apr 2013 |
Dr. Rose is a highly respected physician scientist with focus on clinical investigation, drug discovery, biodefense, and health policy. As a world renowned heart surgeon and scientist, Dr. Rose led the Columbia Presbyterian heart transplantation program from 1982 through 1992 and made history in 1984 when he performed the first successful pediatric heart transplant. From 1994 through 2007, he served as Chairman of Columbia University's Department of Surgery and Surgeon in Chief of Columbia Presbyterian Medical Center in New York.
|
Mr William (Bill) A Burns | Non-Executive DirectorVice-Chairman | Mar 2014 |
Mr. Burns pent his entire management career at the Beecham Group and F. Hoffmann La Roche Ltd. Mr Burns was Chief Executive Officer of Roche Pharmaceuticals from 2001 to 2009, when he joined the Board of Directors of F. Hoffmann La Roche until he retired in 2014. He is the Chair of Molecular Partners, and has been a Non Executive Director of Shire PLC, Chugai Pharmaceutical Co., Genentech, Crucell, and Chairman of Biotie Therapies Corp. from 2014 until its sale to Acorda Therapeutics Inc. in 2016.
|
Ms Jane Catherine Bell | Non-Executive Director | Aug 2022 |
Ms. Bell is a banking and finance lawyer with 30 years experience in international law firms, financial services and corporate treasury operations focusing on international investment transactions in the United States, Canada, Australia and the United Kingdom. She has served as a non executive Director in a diverse range of highly regulated sectors including delivery of healthcare, life sciences, medical research, and funds management.
|
Mr Joseph R Swedish | Non-Executive DirectorNon-Executive Chairman | Jun 2018 |
Mr Swedish has more than two decades of healthcare leadership experience as the CEO for major United States healthcare enterprises. For 12 consecutive years, Modern Healthcare named Mr Swedish as one of the 100 Most Influential People in Healthcare, ranking in the top 20 of the health sector's most senior level executives, highlevel government administrators, elected officials, academics, and thought leaders for five consecutive years. Prior to joining Anthem, Mr. Swedish was CEO for several major integrated healthcare delivery systems.
|
Mr Philip J. Facchina | Non-Executive Director | Mar 2021 |
Mr. Facchina brings more than 35 years of experience in corporate strategy, finance, and business development across several industries, including healthcare. Since 2018, Mr. Facchina has been Chief Strategy Officer at SurgCenter, overseeing the company's strategic relationships, including its relationships with the broad US ambulatory surgical center (ASC) market and its constituents. Prior to SurgCenter, Mr. Facchina spent two decades in the public and private capital markets, where he directly managed public and private capital transactions of equity and debt, led M&A and special advisory processes including take privates.
|
Dr Philip R Krause | Non-Executive Director | Mar 2022 |
With over 30 years of experience at the Food and Drug Administration, Dr. Krause has a unique combination of scientific, regulatory, clinical, and public health experience. He is a physician with board certification in internal medicine and infectious diseases and a researcher with over 100 publications on topics spanning clinical evaluation of vaccines, viral pathogenesis and immunology, and biological product development. He is currently an independent consultant, providing strategic and regulatory advice related to biological product development. He recently served as deputy director of FDA's Office of Vaccines Research and Review, where he led assessments of biological products for evaluation and licensure and helped to oversee the development and evaluation of all vaccines authorized and licensed in the US from 2011 to 2021.
|
Ms Niva Sivakumar | Joint Company Secretary | Oct 2019 |
-
|
Mr Paul Hughes | Joint Company Secretary | Apr 2022 |
-
|
Andrew Chaponnel | Chief Financial Officer (interim) |
-
|
|
Dagmar Rosa Bjorkeson | Chief Operating Officer |
-
|
|
Peter Howard | General Counsel |
-
|
|
Justin Horst | Head of Manufacturing |
-
|
|
Geraldine Storton | Head of Regulatory Affairs and Quality Management |
-
|
|
Niva Sivakumar | Joint Company Secretary |
-
|
|
Paul Hughes | Joint Company Secretary |
-
|
|
Michael Schuster | Pharma Partnering |
-
|
|
Paul Simmons | Scientific Advisor to the Chief Executive Officer |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
J P Morgan Nominees Australia Pty Limited | 203,355,244 | 25.04% |
Hsbc Custody Nominees (Australia) Limited | 84,795,597 | 10.44% |
Professor Silviu Itescu | 67,751,838 | 8.34% |
Citicorp Nominees Pty Limited | 36,878,513 | 4.54% |
Ubs Nominees Pty Ltd | 14,530,688 | 1.79% |
Bnp Paribas Noms Pty Ltd | 12,675,143 | 1.56% |
Thorney Holdings Pty Ltd | 10,000,000 | 1.23% |
Tiga Trading Pty Ltd | 10,000,000 | 1.23% |
Independent Asset Management Pty Limited | 7,585,558 | 0.93% |
Merrill Lynch (Australia) Nominees Pty Limited | 5,611,867 | 0.69% |
National Nominees Limited | 4,014,582 | 0.49% |
Mr Gregory John Matthews & Mrs Janine Marie Matthews | 3,841,063 | 0.47% |
Bnp Paribas Nominees Pty Ltd | 3,484,343 | 0.43% |
Mann Securities Pty Ltd | 2,352,942 | 0.29% |
Lalp Pty Ltd | 1,647,144 | 0.20% |
Dr Siong Wei Hong | 1,501,886 | 0.18% |
Irwin Biotech Nominees Pty Ltd | 1,400,000 | 0.17% |
Beth Sackstein | 1,277,210 | 0.16% |
Mr Muthiah John Hilbert | 1,240,801 | 0.15% |
Bnp Paribas Nominees Pty Ltd Acf Clearstream | 1,204,900 | 0.15% |
Mr Fei Tian | 1,200,000 | 0.15% |